BFH772 (VEGFR2 Inhibitor): Technical Parameters & Workflow Guide

What This Product Solves

BFH772 is a potent and selective inhibitor of the VEGFR2 kinase, engineered to address research needs involving controlled modulation of VEGFR2-mediated angiogenesis. As a VEGFR2 signaling pathway inhibitor, it is particularly applicable to studies requiring high specificity, such as tumor angiogenesis research and models investigating the role of VEGFR2 in pathological neovascularization. The compound's selectivity profile—demonstrating approximately 500-fold reduced potency against related VEGF receptors (FLK-1, FLT-1, FLT-4) and about 40-fold lower efficacy versus other kinases—enables researchers to isolate VEGFR2-dependent mechanisms without confounding off-target effects (source: product_spec).

BFH772 is not suitable for experiments demanding water-soluble inhibitors or those requiring broad-spectrum kinase inhibition, as its solubility is limited to organic solvents and its kinase selectivity is tightly defined (source: internal_article).

Protocol Parameters

• Kinase inhibition assay | IC50 = 3 nM | Suitable for in vitro VEGFR2 kinase activity measurement | Enables precise quantification of VEGFR2 inhibition potency | product_spec
• Solubility in DMSO | ≥53.4 mg/mL | Required for stock solution preparation in organic solvent workflows | High solubility in DMSO facilitates accurate dosing and handling | product_spec
• Solubility in water | Insoluble | Not suitable for aqueous-based protocols | Insolubility in water restricts use to organic solvent-compatible assays | product_spec
• Storage temperature | -20°C | Recommended for long-term compound stability | Prevents degradation and preserves activity; long-term storage of solutions is not advised | product_spec
• In vivo oral administration | As per workflow recommendation | Applicable for tumor growth and angiogenesis inhibition studies in animal models | In vivo data support use in preclinical tumor models, but details must be adapted to protocol | workflow_recommendation

Workflow Setup and QC Checklist

To maximize the technical performance of BFH772 as a selective angiogenesis inhibitor, follow these workflow best practices:

• Stock Solution Preparation: Dissolve BFH772 in DMSO (≥53.4 mg/mL) or ethanol (≥15.33 mg/mL) to create concentrated stocks. Avoid water as a solvent due to insolubility (source: product_spec).
• Aliquoting and Storage: Prepare small aliquots to avoid multiple freeze-thaw cycles. Store solid compound and aliquots at -20°C. Do not store solutions long term; prepare fresh for each experiment.
• Vehicle Control: For in vitro and in vivo studies, match vehicle composition to the solvent used (e.g., DMSO or ethanol). Include vehicle-only controls to differentiate compound effects from solvent background.
• Concentration Range Testing: Begin with sub-nanomolar to low-nanomolar concentrations in kinase assays, referencing the reported IC50 for VEGFR2 inhibition. Empirically optimize for specific cell lines or tissue systems (source: internal_article).
• Quality Control: Use supplied certificates of analysis and purity data (≥96%) to verify lot quality. Confirm compound identity and batch integrity before use.

For detailed stepwise protocols and technical limitations, refer to the internal resource BFH772 (VEGFR2 inhibitor): Technical Guidance & Protocol Setup, which outlines practical workflows and solubility constraints. Additional stepwise guidance is available in BFH772 (VEGFR2 inhibitor): Technical Protocols and Use Guide.

Common Failure Modes and Fixes

• Precipitation in aqueous buffers: Due to insolubility in water, BFH772 may precipitate if directly mixed with aqueous solutions. Fix: Pre-dissolve in DMSO or ethanol, then dilute into working media ensuring final solvent concentration is compatible with assay or cell type.
• Reduced potency in broad kinase panels: BFH772 may not effectively inhibit kinases other than VEGFR2 due to its selectivity profile. Fix: Use only in applications requiring specific VEGFR2 inhibition; choose alternative compounds for multi-kinase inhibition workflows.
• Loss of activity due to improper storage: Repeated freeze-thaw or prolonged solution storage can degrade compound. Fix: Store at -20°C, avoid long-term storage of solutions, and use freshly prepared working stocks.
• Unanticipated cytotoxicity or off-target effects: While BFH772 is highly selective, verify vehicle and concentration effects in each new model system. Fix: Include matched vehicle controls and titrate concentration as needed for each assay type.

Scope and Limitations

BFH772 is best suited for experiments targeting VEGFR2-mediated angiogenesis, including in vitro kinase assays, cell-based signaling studies, and in vivo tumor growth models where selective VEGFR2 inhibition is required. Its high selectivity minimizes confounding off-target kinase effects, making it an appropriate choice for mechanistic studies involving VEGFR2 signaling. However, BFH772 should not be used in protocols requiring water-soluble reagents or broad-spectrum kinase inhibition. Its use is further limited to workflows compatible with organic solvents and requires careful handling to avoid compound precipitation or degradation (source: internal_article).

Researchers should also note that while in vivo applicability is supported in animal tumor models, protocol adaptation is necessary for specific models and endpoints. Long-term storage of solutions is discouraged, and detailed attention to QC data is required prior to use.

Conclusion

BFH772 is a rigorously characterized VEGFR2 inhibitor with high selectivity and potency, optimized for applications requiring targeted inhibition of VEGFR2-driven angiogenesis. Its solubility profile confines its use to DMSO- or ethanol-based workflows, and its technical performance is contingent on adherence to product specifications and best-practice handling. For additional technical documentation and ordering information, see BFH772 (VEGFR2 inhibitor) at APExBIO.